Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADVIL COLD AND SINUS vs ALCAFTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Temporary relief of sinus congestion and pressure,Temporary relief of nasal congestion,Temporary reduction of fever,Relief of minor aches and pains associated with the common cold or flu
FDA: Prevention of itching associated with allergic conjunctivitis,Off-label: No established off-label uses
1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
Ibuprofen: 2-4 hours (terminal; rapid elimination, no accumulation with intermittent use). Pseudoephedrine: 4-8 hours (terminal; prolonged in alkaline urine, up to 16 hours at p H 8).
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Ibuprofen is primarily metabolized by CYP2C9 and CYP2C8. Pseudoephedrine is partially metabolized in the liver by N-demethylation.
Not extensively metabolized; primarily excreted unchanged in urine. Cytochrome P450 metabolism is minimal.
Renal excretion of unchanged drug and metabolites: ibuprofen ~45-60% (primarily as conjugated metabolites, <10% unchanged), pseudoephedrine ~70-90% unchanged. Biliary/fecal elimination accounts for <10% for both components.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Ibuprofen: ~99% primarily to albumin. Pseudoephedrine: negligible (<10% bound to plasma proteins).
Approximately 40% bound to plasma proteins.
Ibuprofen: 0.1-0.2 L/kg (low Vd, indicating limited tissue distribution). Pseudoephedrine: 2.5-3.5 L/kg (high Vd, extensive tissue distribution including CNS).
Vd is approximately 1.4 L/kg, indicating distribution beyond plasma into extravascular tissues.
Oral: ibuprofen ~80-100% (rapidly absorbed, no significant first-pass). Pseudoephedrine ~100% (well absorbed, minimal first-pass metabolism).
Systemic bioavailability after topical ocular administration is low (estimated < 0.5%) due to dilution, local metabolism, and limited corneal penetration.
GFR 30-89 m L/min: Use lowest effective dose for shortest duration; monitor renal function. GFR <30 m L/min or dialysis: Contraindicated.
No dose adjustment required for any degree of renal impairment.
Child-Pugh Class A: No adjustment; use with caution. Child-Pugh Class B or C: Avoid use.
No dose adjustment required for any degree of hepatic impairment.
Children <12 years: Do not use. Children ≥12 years: Same as adult dosing; 1-2 tablets every 4-6 hours as needed; maximum 6 tablets in 24 hours.
Children 2 years and older: same as adult dose. Safety and efficacy in children under 2 years not established.
Use lowest effective dose for shortest duration; avoid chronic use. Reduce initial dose to 1 tablet every 6-8 hours due to increased risk of renal impairment, GI bleeding, and cardiovascular events.
No specific dose adjustment needed; use same dose as for younger adults.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
None
Cardiovascular thrombotic events, gastrointestinal bleeding/ulceration/perforation, hypertension, renal toxicity, serious skin reactions, anaphylactoid reactions, exacerbation of asthma, and drug interactions including with ACE inhibitors, diuretics, and lithium.
Do not inject; for topical ophthalmic use only,Avoid wearing contact lenses if eyes are red,May cause temporary blurred vision after instillation,Use with caution in patients with known hypersensitivity
Hypersensitivity to ibuprofen, aspirin, or other NSAIDs; history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; patients with severe hypertension or coronary artery disease; patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping MAOIs; concurrent use of other sympathomimetics; in the setting of CABG surgery.
Hypersensitivity to alcaftadine or any component of the formulation
Take with food or milk to reduce gastrointestinal irritation. Avoid alcohol consumption as it increases the risk of NSAID-related gastric ulcers and bleeding. High-sodium foods may exacerbate hypertension in patients sensitive to the pressor effects of pseudoephedrine.
No specific food interactions reported. As an ophthalmic preparation, systemic absorption is minimal and unlikely to be affected by food.
First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.62) for any malformation and 1.86 (95% CI 1.32-2.62) for cardiac malformations. Second trimester: Risk of oligohydramnios and premature closure of ductus arteriosus after 20 weeks. Third trimester: Avoid after 30 weeks due to risk of premature ductus arteriosus closure and oligohydramnios; after 32 weeks, increased risk of necrotizing enterocolitis, intracranial hemorrhage, and renal impairment in neonate (renal agenesis/dysgenesis). Pseudoephedrine: First trimester – possible increased risk of gastroschisis (odds ratio 1.8, 95% CI 1.0-3.2) and small intestinal atresia. Second and third trimesters: potential uteroplacental vasoconstriction leading to fetal hypoxia; risk of prematurity and low birth weight.
Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, alcaftadine should be used during pregnancy only if clearly needed.
Ibuprofen: M/P ratio 0.005–0.006; low transfer into breast milk; AAP compatible; theoretical risk of platelet dysfunction in neonate. Pseudoephedrine: M/P ratio 2.6–3.5 (concentrated in milk); estimated infant dose 4.3% of maternal weight-adjusted dose; may cause irritability and sleep disturbances in infant; may reduce milk production by up to 24%. Caution advised; avoid in lactation if possible.
It is not known whether alcaftadine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when alcaftadine is administered to a nursing woman. The M/P ratio has not been established.
Ibuprofen: No dose adjustment required; however, use lowest effective dose and shortest duration; avoid after 30 weeks gestation. Pseudoephedrine: No specific dose adjustment recommended based on pharmacokinetic changes, but use with caution due to vasoconstrictive effects; reduced efficacy may be observed due to increased plasma volume and renal clearance.
No pharmacokinetic studies have been performed in pregnant women. Based on the available animal data and the low systemic exposure after ocular administration, no dosing adjustment is recommended during pregnancy.
Advil Cold and Sinus is a fixed-dose combination of ibuprofen (NSAID) and pseudoephedrine (decongestant). Ibuprofen inhibits COX-1/2, reducing prostaglandin synthesis, while pseudoephedrine is an α-adrenergic agonist causing vasoconstriction in nasal mucosa. Use cautiously in patients with hypertension, cardiovascular disease, or renal impairment due to pseudoephedrine's pressor effects and ibuprofen's potential to reduce renal blood flow and antagonize antihypertensives. Avoid in patients with severe coronary artery disease, uncontrolled hypertension, or concurrent MAOI use. Max duration: 3 days for sinus symptoms, 5 days for pain. Monitor for NSAID-induced GI bleeding, especially in elderly or those on anticoagulants/aspirin.
ALCAFTADINE is a topical ophthalmic antihistamine and mast cell stabilizer used for allergic conjunctivitis. Administer one drop twice daily in each affected eye. Onset of action is within minutes. Contraindicated in patients with hypersensitivity to any component. Use with caution in contact lens wearers; remove lenses before instillation and wait 10 minutes before reinserting. Do not touch dropper tip to any surface to avoid contamination.
Do not take more than directed; do not exceed 6 caplets in 24 hours.,Avoid use with other products containing ibuprofen or other NSAIDs, including aspirin, to prevent overdose and serious side effects.,Discontinue use and seek medical attention if symptoms worsen, persist >3 days for sinus or >5 days for pain, or if new symptoms occur.,Take with food or milk to reduce stomach upset; avoid alcohol to lower risk of GI bleeding.,If you have high blood pressure, heart disease, thyroid disease, diabetes, or difficulty urinating due to prostate enlargement, consult a doctor before use.,Do not use if you are taking a prescription monoamine oxidase inhibitor (MAOI) or for 2 weeks after stopping an MAOI drug.,Pregnant or breastfeeding women should not use this product; ibuprofen is contraindicated in third trimester due to risk of premature closure of ductus arteriosus.,Store at room temperature away from moisture and heat.
Do not wear contact lenses if your eyes are red; after the redness subsides, wait at least 10 minutes after instilling the drop before reinserting lenses.,Do not touch the dropper tip to your eye or any surface to avoid contamination.,Wait at least 5 minutes between using this drug and other eye drops.,If you miss a dose, use it as soon as you remember; if it is almost time for the next dose, skip the missed dose and resume your regular schedule.,Do not use more than prescribed; overuse may cause eye irritation.,Tell your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Wash hands before and after use.
No interactions on record
"Dextroamphetamine, a central nervous system stimulant, may reduce the sedative effects of Alcaftadine, an antihistamine used for allergic conjunctivitis, by opposing its central histamine H1 receptor blockade. This pharmacodynamic antagonism can lead to diminished sedation and potentially decreased therapeutic efficacy of Alcaftadine for its intended ocular antiallergic effects. Patients may experience reduced symptom relief and increased ocular discomfort."
"Hydroxyamphetamine may decrease the sedative activities of Alcaftadine."
"Phentermine may decrease the sedative activities of Alcaftadine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADVIL COLD AND SINUS vs ALCAFTADINE, answered by our medical review team.
ADVIL COLD AND SINUS is a NSAID/Decongestant Combination that works by Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, leading to analgesic, anti-inflammatory, and antipyretic effects. Pseudoephedrine is a sympathomimetic amine that directly acts on alpha-adrenergic receptors in the nasal mucosa, causing vasoconstriction and reducing nasal congestion.. ALCAFTADINE is a Ophthalmic Antihistamine that works by Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADVIL COLD AND SINUS and ALCAFTADINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADVIL COLD AND SINUS is: 1-2 tablets (each containing ibuprofen 200 mg and pseudoephedrine 30 mg) orally every 4-6 hours as needed; maximum 6 tablets in 24 hours. Do not exceed 1200 mg ibuprofen and 180 mg pseudoephedrine per day.. The standard adult dose of ALCAFTADINE is: 1 drop of 0.25% ophthalmic solution in each affected eye twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADVIL COLD AND SINUS and ALCAFTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADVIL COLD AND SINUS is classified as Category C. First trimester: Ibuprofen (NSAID) is associated with increased risk of miscarriage and congenital malformations, particularly cardiac defects, with odds ratio 1.86 (95% CI 1.32-2.. ALCAFTADINE is classified as Category C. Alcaftadine is classified as Pregnancy Category B. Animal studies have not demonstrated teratogenic effects at doses up to 2400 times the human ocular dose. There are no adequate a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.